GRI BIO Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 16. FORM 10-K SUMMARY
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GRI BIO, INC. | ||
| Date: March 28, 2024 | By: | /s/ W. Marc Hertz |
|---|---|---|
| Name: W. Marc Hertz, Ph.D. | ||
| Title: President and Chief Executive Officer | ||
SIGNATURES AND POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Baker as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and all documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ W. Marc Hertz, Ph.D. | President, Chief Executive Officer and Director(Principal Executive Officer) | March 28, 2024 |
| W. Marc Hertz, Ph.D. | ||
| /s/ Leanne Kelly | Chief Financial Officer (Principal Financial and Accounting Officer) | March 28, 2024 |
| Leanne Kelly | ||
| /s/ David Szekeres | Director, Chair of the Board | March 28, 2024 |
| David Szekeres | ||
| /s/ David Baker | Director | March 28, 2024 |
| David Baker | ||
| /s/ Roelof Rongen | Director | March 28, 2024 |
| Roelof Rongen | ||
| /s/ Camilla V. Simpson, M.Sc. | Director | March 28, 2024 |
| Camilla V. Simpson, M.Sc. | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and December 31, 2022 | F-3 |
| Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.